Slide 1: APG808 Phase 1b interim results
Title text 2 MAY 12, 2025 APG808 Phase 1b interim results
Slide 2: Forward-looking statements
2 © Apogee Therapeutics, Inc APG808 PHASE 1b This presentation contains certain "forward - looking statements" within the meaning of applicable securities laws. Other than sta tements of historical facts, all statements included in this presentation are forward - looking statements, including statem
Slide 3: APG808 Phase 1b interim data met or exceeded trial objectives
3 © Apogee Therapeutics, Inc APG808 Phase 1b interim data met or exceeded trial objectives APG808 PHASE 1b NOTE: 1 Mean change from baseline in FeNO (ppb) and mean percent change from baseline FeNO , maximum mean reduction at D36. FeNO = fractional exhaled nitric oxide. Ppb = parts per billion. Data
Slide 4: Phase 1b trial design elements and schematic
4 © Apogee Therapeutics, Inc Design elements Schematic Double - blind, placebo - controlled two - dose regimen in patients with asthma N = 22 1 Key inclusion criteria: • Mild - to - moderate asthma • FeNO ≥25 ppb Primary endpoint: safety Additional endpoints: change in fractional exhaled nitric oxid
Slide 5: Baseline characteristics are in line with expectations
5 © Apogee Therapeutics, Inc APG808 PHASE 1b Baseline characteristics are in line with expectations NOTE: 1 APG808 safety population includes 1 patient who was misdosed (received placebo at D1 and active dose D29). 2 Tobacco use is inclusive of cigarettes, cigars, and smokeless tobacco or nicotine p
Slide 6: Multiple doses of APG808 were well-tolerated in mild-to-moderate asthma patients
6 © Apogee Therapeutics, Inc APG808 PHASE 1b Multiple doses of APG808 were well - tolerated in mild - to - moderate asthma patients NOTE: TEAE = Treatment - Emergent Adverse Event. 1 1 patient was misdosed (received placebo on D1 and active dose on D29) but remains included in the APG808 safety popu
Slide 7: Adverse events occurring in ≥5% of total population
© Apogee Therapeutics, Inc 7 APG808 PHASE 1b Multiple Dose APG808 600 mg D1, D29 N=17 Placebo D1, D29 N=5 AE occurring in ≥5% of total population 1 n (%) 8 (47.1%) 2 (40.0%) Headache 3 (17.6%) 0 (0.0%) Injection site erythema 2 (11.8%) 1 (20.0%) Upper respiratory tract infection 1 (6.3%) 1 (16.7%) 2
Slide 8: APG808 rapidly and durably suppressed FeNO through week 12
8 © Apogee Therapeutics, Inc APG808 PHASE 1b APG808 rapidly and durably suppressed FeNO through week 12 Maximum FeNO change from baseline FeNO change from baseline APG808 600 mg D1, D29 (N=15) APG808 showed greater mean FeNO reduction relative to DUPIXENT Placebo D1, D29 (N=5) - 40 - 30 - 20 - 10 0
Slide 9: APG808 rapidly and durably suppressed FeNO: percent change from baseline
9 © Apogee Therapeutics, Inc APG808 PHASE 1b APG808 rapidly and durably suppressed FeNO through week 12 Maximum percent FeNO change from baseline FeNO percent change from baseline APG808 600 mg D1, D29 (N=15) Placebo D1, D29 (N=5) - 60 0 - 40 - 20 NOTE: 2 patients were excluded from FeNO analysis po
Slide 10: APG808 suppressed pSTAT6 and showed changes in TARC similar to DUPIXENT
10 © Apogee Therapeutics, Inc APG808 PHASE 1b APG808 rapidly and durably suppressed pSTAT6 and showed changes in TARC similar to DUPIXENT Median % pSTAT6 APG808 TARC suppression was similar to DUPIXENT APG808 shows near - complete pSTAT6 inhibition for ~3 months APG808 600 mg D1, D29 (N=16) Placebo
Slide 11: Apogee definition
Apogee /ˈ apəjē / noun The highest point in the development of something; a climax or culmination